Breast Cancer Conversations: What You Need To Know About Your Metabolic Health and Breast Cancer
Breast Cancer Conversations: What You Need To Know About Your Metabolic Health and Breast Cancer
What You Need To Know About Your Metabolic Health and Breast Cancer Breast Cancer Conversations is a podcast that discusses all things breast cancer! We share stories of those who have been diagnosed. We interview medical professionals, doctors, radiologists, and oncologists. We speak with advocates and caregivers. We are your voice! If you have questions, […]
SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show
SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatment.
AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients
SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical […]
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
…insulin signaling can be seen as enabling tumor development by providing a mechanism for PI3K activation and enhanced glucose uptake. This idea is supported by studies showing enhanced tumor development in humans and mice with hyperinsulinemia, and reduced tumor development in states of reduced insulin levels.
Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer
Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).
Diabetes Increases Breast Cancer Mortality Risk
Women with breast cancer and diabetes have a greater risk for all-cause and cancer-specific mortality and are less likely to receive chemotherapy and radiotherapy compared with women with breast cancer alone, according to researchers.
40 percent of US cancers linked to excess weight
About 40 percent of all cancers in the United States -- more than 630,000 in all -- are associated with excess weight, health officials said Tuesday, urging a renewed focus on prevention. The rates of these overweight- and obesity-related cancers are rising, in contrast to the overall rate of new cancer cases which has dropped since the 1990s.
ESMO 2017 Press Release: Abdominal Fat a Key Cancer Driver for Postmenopausal Women
"When assessing cancer risk, body mass index (BMI) and fat percentage may not be adequate measures as they fail to assess the distribution of fat mass," she explained. "Avoiding central obesity may confer the best protection."
Throwing oil into the flames
Obesity has become one of the leading preventable causes of cancer. Yet, the mechanisms of how obesity and associated systemic inflammation can promote cancer progression remain poorly understood. In a new study, researchers found that the cytokines interleukin 5 (IL-5) and granulocyte macrophage colony-stimulating factor (GM-CSF) are induced in obesity and, in obese mice, this leads to lung neutrophilia and supports breast cancer metastasis to the lung. Quail, Olson et al. used mouse models of obesity, induced by a high-fat diet (diet-induced obesity, DIO mice) or leptin deficiency (ob/ ob mice), to study how inflammation in obesity is linked to breast cancer metastasis.
SynDevRx will be attending ASCO (Chicago) June 3–7
The ASCO Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.